Skip to main content
JUNS
NASDAQ Life Sciences

Jupiter Neurosciences Secures 3-Month Extension on Convertible Note Payments

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$0.52
Mkt Cap
$17.898M
52W Low
$0.48
52W High
$3.33
52W Position info
8.3% above low
Off High info
84% below high
Rel. Volume info
0.1× avg
Market data snapshot near publication time

JUNS is trading near its 52-week low of $0.48 (8.3% above the low) on light trading volume (0.1× avg).

Summary

Jupiter Neurosciences amended its $6.0 million convertible notes, delaying monthly payments by three months and revising the payment schedule, providing immediate liquidity relief.


Key Events · Financing and Capital Events · JUNS

  • Convertible Note Amendment

    The company entered into an Omnibus Amendment with YA II PN, LTD, modifying the terms of its $6.0 million convertible promissory notes.

  • Payment Extension Granted

    Monthly installment payments for the convertible notes will now commence on April 1, 2026, an extension of approximately three months from the previous schedule.

  • Revised Payment Schedule

    The amendment introduces a variable payment schedule for the notes and updates provisions related to Advance Notices under the Standby Equity Purchase Agreement (SEPA).

  • Enhanced Financial Flexibility

    This extension provides Jupiter Neurosciences with additional time and flexibility in managing its cash flow and debt obligations.


Analysis · JUNS · Life Sciences

Jupiter Neurosciences, a life sciences company, has amended its existing $6.0 million convertible promissory notes with Yorkville, pushing back the start of monthly installment payments by approximately three months to April 1, 2026. This provides the company with crucial short-term financial flexibility and extends its cash runway, which is particularly important for a small-cap biotech firm managing development costs. The amendment also introduces a variable payment schedule and clarifies how proceeds from future equity sales under the Standby Equity Purchase Agreement (SEPA) will be allocated, with 50% potentially used to prepay future installments.

At the time of this filing, JUNS was trading at $0.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $17.9M. The 52-week trading range was $0.48 to $3.33. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

JUNS - Latest Insights

JUNS
Jul 21, 2026, 4:07 PM EDT
Filing Type: 424B3
Importance Score:
8
Price at Filing: $0.1688
Real-time Price: $0.1199 info
Change: -$0.0489 (-29%) info
Market Cap: $5.835M info
JUNS
Jul 21, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.1679
Real-time Price: $0.1199 info
Change: -$0.048 (-29%) info
Market Cap: $5.835M info
JUNS
Jul 21, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $0.2153
Real-time Price: $0.1199 info
Change: -$0.0954 (-44%) info
Market Cap: $5.835M info
JUNS
Jun 30, 2026, 5:29 PM EDT
Filing Type: 424B3
Importance Score:
7
Price at Filing: $0.214
Real-time Price: $0.1199 info
Change: -$0.0941 (-44%) info
Market Cap: $5.835M info
JUNS
Jun 30, 2026, 5:07 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.214
Real-time Price: $0.1199 info
Change: -$0.0941 (-44%) info
Market Cap: $5.835M info